Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
ANNEXA-I: Andexanet Alfa Shows Efficacy, Safety for Factor Xa Reversal in Acute ICH
October 27th 2023The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
Read More
Dr Melissa Levine on Implementing Value-Based Care in the Primary Care Setting
October 26th 2023Melissa Levine, MD, a family medicine specialist at Arizona Community Physicians and medical director for the Abacus Health accountable care organization (ACO), discussed strategies for succeeding in an ACO and how primary care can complement oncology care for patients with cancer.
Read More
Zanubrutinib Associated With Better OS in Second vs Later Lines of R/R MCL Therapy
October 23rd 2023A pooled analysis with nearly 3 years of follow-up showed better outcomes when zanubrutinib was given in the second line vs later lines of therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Read More
Intensive Therapy More Effective vs Less Intense Therapy in Frail Patients With MM
October 20th 2023A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.
Read More
Many Cases of Adult-Onset T1D Are Diagnosed After Age 30, Study Finds
October 7th 2023In the overall population of more than 1.3 million US adults, 37% of patients reported being diagnosed with T1D after 30 years, with men and racial or ethnic minorities diagnosed later compared with women and non-Hispanic White adults.
Read More
Innovations in Cancer Care Improve Outcomes, but Cost Remains a Barrier: Christine Pfaff, RPh
October 6th 2023Christine Pfaff, RPh, senior regional director of operations at American Oncology Network, discusses the role of immunotherapy and precision medicine in oncology, as well as considerations for patient safety and financial toxicity when prescribing oncology drugs.
Read More
Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL
October 6th 2023Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.
Read More
Review Highlights Potential of Neoadjuvant Immune Checkpoint Inhibition in Multiple Cancers
September 30th 2023Recent evidence suggests that neoadjuvant immunotherapy offers a unique opportunity to explore disease mechanisms and identify new biomarkers of immune checkpoint blockade response and resistance, according to the researchers.
Read More
Patients With T1D Report Improved Management Using DIY-CGM vs isCGM
September 25th 2023The study aimed to determine the perceived advantages and disadvantages of the smartwatch-integrated, do-it-yourself continuous glucose monitoring (DIY-CGM) device from the perspective of patients with type 1 diabetes (T1D).
Read More
Sociodemographic, Clinical Variables Impact Metabolic Control in Adolescents With T1D
September 22nd 2023Self-care adherence, family support and functioning, and school support also indirectly affected the relationship between sociodemographic and clinical variables and metabolic control, a study found.
Read More
First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC
September 20th 2023In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Read More
Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis
September 20th 2023In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
Read More
Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL
September 15th 2023A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
Long-Term Data Show Consistent OS Benefit With Nivolumab Plus Ipilimumab in mNSCLC
September 13th 2023The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
Read More
AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements
September 8th 2023A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
Read More
National Alliance Guideline Identifies Key PBM Concerns for Health Plan Purchasers
September 7th 2023The playbook includes resources for purchasers to help in their dealings with pharmacy benefit managers (PBMs), including best practice checklists, sample questionnaires for choosing consultants, and recommendations for contracting language.
Read More
Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs
September 7th 2023The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.
Read More
Dr Sachin Jain on the Changing Doctor-Patient Relationship and Middlemen in Health Care
September 1st 2023Sachin Jain, MD, MBA, president and CEO at SCAN Group and SCAN Health Plan, discussed the growing roles of middlemen between physicians and their patients in an increasingly complex system.
Read More
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
August 26th 2023A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Read More
Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL
August 23rd 2023Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Read More
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
August 18th 2023The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
Read More